Scholars@Duke
Sanghee Hong

Sanghee Hong

Assistant Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
sanghee.hong@duke.edu
2400 Pratt Street, Box 3961, Durham, NC 27710

Selected Publications

Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation.

Journal Article Transplant Cell Ther · October 2024 BACKGROUND: Umbilical cord blood transplant (UCBT) improves access to transplant for patients lacking a fully matched donor. Previous Center for International Blood and Marrow Transplant Research (CIBMTR) showed that Black patients had a lower overall surv ... Full text Link to item Cite

Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities.

Journal Article Blood Adv · July 9, 2024 There has been an increase in volume as well as an improvement in overall survival (OS) after hematopoietic cell transplantation (HCT) for hematologic disorders. It is unknown if these changes have affected racial/ethnic minorities equally. In this observa ... Full text Link to item Cite

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.

Journal Article Blood · June 27, 2024 Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Despite extensive data supporting its use, outcomes stratified by race and ethn ... Full text Link to item Cite

A More MAGICal Alogrithm in Acute GVHD.

Journal Article Transplant Cell Ther · April 2024 Full text Link to item Cite

A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease.

Journal Article Transplant Cell Ther · July 2023 Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Acute GVHD is associated with severe physical and psychosocial symptoms. We sought to evaluate the feasibility of ... Full text Link to item Cite

Health-Related Quality of Life in Double Umbilical Cord Blood versus Haploidentical Marrow Transplantation: A Quality of Life Analysis Report of BMT CTN 1101.

Journal Article Transplant Cell Ther · July 2023 The Blood and Marrow Transplant Clinical Trials Network study 1101 (BMT CTN 1101; ClinicaTrials.gov identifier NCT01597778) was a multicenter phase III randomized trial comparing the clinical outcomes and quality of life (QoL) of patients with hematologic ... Full text Link to item Cite

Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.

Journal Article Nat Commun · May 31, 2023 Graft-versus-leukemia (GvL) reactions are responsible for the effectiveness of allogeneic hematopoietic cell transplantation as a treatment modality for myeloid neoplasia, whereby donor T- effector cells recognize leukemia neoantigens. However, a substanti ... Full text Link to item Cite

Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.

Journal Article Res Sq · April 5, 2023 Graft-versus-leukemia (GvL) reactions are responsible for the effectiveness of allogeneic hematopoietic cell transplantation as a treatment modality for myeloid neoplasia, whereby donor T- effector cells recognize leukemia neoantigens. However, a substanti ... Full text Link to item Cite

Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors.

Journal Article Transplant Cell Ther · March 2023 The use of hematopoietic cell transplantation (HCT) has been increasing in older patients. However, the levels if distress, psychosocial functioning, and health-related quality of life (HRQOL) among older HCT survivors remains largely unknown. In this seco ... Full text Link to item Cite

Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy.

Journal Article Transplant Cell Ther · October 2022 Chronic graft-versus-host disease (cGVHD) occurs in up to 25% of children following allogeneic hematopoietic cell transplantation (HCT) and continues to be a major cause of late morbidity and poor quality of life among long-term survivors of pediatric HCT. ... Full text Link to item Cite

Comparison of Quality of Life and Outcomes between Haploidentical and Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.

Journal Article Transplant Cell Ther · April 2022 Haploidentical (haplo) donor grafts are a well-established alternative donor source for allogeneic hematopoietic cell transplantation (HCT); however, data comparing health-realted quality of life (HRQOL) measures between haplo-HCT and HCT using other donor ... Full text Link to item Cite

Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics.

Journal Article Hematology Am Soc Hematol Educ Program · December 10, 2021 Allogeneic hematopoietic cell transplantation (HCT) is particularly susceptible to racial, socioeconomic, and geographic disparities in access and outcomes given its specialized nature and its availability in select centers in the United States. Nearly all ... Full text Link to item Cite

Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era.

Journal Article Hematol Oncol Stem Cell Ther · December 2021 OBJECTIVE/BACKGROUND: Relapse is the most common cause of treatment failure after allogeneic hematopoietic cell transplantation (alloHCT). No standard of care exists, and a wide range of treatments are used for post-alloHCT relapse. In the recent era, seve ... Full text Link to item Cite

Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia.

Journal Article Transplant Cell Ther · November 2021 Natural killer (NK) cells are regulated by killer immunoglobulin-like receptor (KIR) interactions with human leukocyte antigen class I ligands. Various models of NK cell alloreactivity have been associated with outcomes after allogeneic hematopoietic cell ... Full text Link to item Cite

Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.

Journal Article Transplant Cell Ther · August 2021 Young adult (YA) survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for late psychosocial challenges, including the inability to return to work post-HCT. Work-related outcomes in this population remain understudied, however. We co ... Full text Link to item Cite

Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation.

Journal Article JCI Insight · July 8, 2021 TCR repertoire diversification constitutes a foundation for successful immune reconstitution after allogeneic hematopoietic cell transplantation (allo-HCT). Deep TCR Vβ sequencing of 135 serial specimens from a cohort of 35 allo-HCT recipients/donors was p ... Full text Link to item Cite

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

Journal Article JAMA Oncol · July 1, 2021 IMPORTANCE: Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy and autologous hematopoietic cell transplant (AHCT) is an accepted and effective consolidation strategy for PCNSL, ... Full text Link to item Cite

Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.

Journal Article Cancer · February 15, 2021 BACKGROUND: The association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Tran ... Full text Link to item Cite

Social Issues

Chapter · January 1, 2021 Hematopoietic cell transplantation (HCT) is potentially curative for many high-risk hematologic and non-hematologic diseases. This chapter focuses on social issues relevant for HCT recipients throughout the transplantation process. Disparities in healthcar ... Full text Cite

To D or not to D: vitamin D in hematopoietic cell transplantation.

Journal Article Bone Marrow Transplant · November 2020 Vitamin D plays an essential role in bone health, immune tolerance, and immune modulation. Autologous and allogeneic hematopoietic cell transplantation (HCT) recipients are at increased risk of vitamin D deficiency, which may increase risks of bone loss an ... Full text Link to item Cite

Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation.

Journal Article Biol Blood Marrow Transplant · December 2019 Malignancy relapse is the most common cause of treatment failure among recipients of hematopoietic cell transplantation (HCT). Conditioning dose intensity can reduce disease relapse but is offset by toxicities. Improvements in radiotherapy techniques and s ... Full text Link to item Cite

Psychosocial Assessment of Candidates for Transplant (PACT) as a tool for psychological and social evaluation of allogeneic hematopoietic cell transplantation recipients.

Journal Article Bone Marrow Transplant · September 2019 Psychosocial Assessment of Candidates for Transplant (PACT) is a tool originally developed to address psychosocial risks in solid organ transplant recipients and has the potential for application to hematopoietic cell transplantation (HCT) recipients. In a ... Full text Link to item Cite

Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.

Journal Article Blood Adv · June 12, 2018 Busulfan combined with cyclophosphamide (BuCy) has long been considered a standard myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (HCT), including both nonmalignant conditions and myeloid diseases. Substituting fludara ... Full text Link to item Cite

Community Risk Score for Evaluating Health Care Disparities in Hematopoietic Cell Transplantation.

Journal Article Biol Blood Marrow Transplant · April 2018 There is a critical need for tools to comprehensively describe disparities in hematopoietic cell transplant (HCT) recipients. We conducted a retrospective cohort study to evaluate a Community Risk Score (CRS) tool for this purpose. CRS included 10 communit ... Full text Link to item Cite

Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.

Journal Article Bone Marrow Transplant · September 2016 Socioeconomic status (SES) is an important determinant of disparities in health care. The association of SES with outcomes in autologous hematopoietic cell transplantation (AHCT) has not been described previously. We conducted a retrospective cohort study ... Full text Link to item Cite

Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.

Journal Article Biol Blood Marrow Transplant · June 2016 Autologous hematopoietic cell transplantation (AHCT) is standard therapy for eligible patients with multiple myeloma. Health care disparities can influence transplantation outcomes. However, the association of socioeconomic status (SES), a major indicator ... Full text Link to item Cite

Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders.

Journal Article Bone Marrow Transplant · March 2015 Hematopoietic cell transplantation (HCT) with non-myeloablative (NMA) conditioning for lymphoproliferative diseases (LD) includes fludarabine with and without low-dose TBI. Transplant outcomes were compared among patients aged ⩾40 years with LD who receive ... Full text Link to item Cite